<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02854670</url>
  </required_header>
  <id_info>
    <org_study_id>P/2013/199</org_study_id>
    <nct_id>NCT02854670</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of Topical Capsaicin in the Treatment of Provoked Vestibulodynia</brief_title>
  <acronym>CAPSIVU</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the pain on contact in provoked vestibulodynia, measured with
      Visual Analogic Scale at week 0/week 2/week 6/week 12 after applying a patch of capsaicin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessment with Visual Analogic Scale (using a q-tip)</measure>
    <time_frame>week 12</time_frame>
    <description>Assessment of provoked pain with Visual Analogic Scale (using a q-tip)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Vestibulodynia</condition>
  <arm_group>
    <arm_group_label>Capsaicin patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cuttable capsaicin patch. 2 patches of 4 cm² (2 x 2cm), for a total of 2.5 mg of capsaicin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capsaicin patch</intervention_name>
    <description>After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.</description>
    <arm_group_label>Capsaicin patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provoked vulvodynia, rated B2a according to 2003 International Society for the Study
             of Vulvovaginal Disease (ISSVD) classification

          -  Pain ≥ 4 on Visual Analogic Scale (VAS)

          -  Subject refractory to at least 2 conventional treatments (tricyclic antidepressants,
             anticonvulsants at analgesic doses , biofeedback physical therapy, psychological
             assessment in a context of chronic pain) or to botulinum toxin A

          -  If a former treatment with botulinum toxin A was performed: patient must be in
             treatment failure (= no decrease over 50% of the pain 3 months after initiation of the
             treatment)

          -  Negative screening test results

          -  Menopause, surgically sterilized women or women using effective contraceptive method

          -  Good understanding and predictable adherence to the protocol

          -  Beneficiary/affiliated to French social security/social healthcare

          -  Signed Informed Consent Form

        Exclusion Criteria:

          -  Predictable poor adherence

          -  Pregnant or breastfeeding women

          -  Diabetes mellitus type 1 or type 2

          -  Major mental disorders

          -  Underlying etiology such as chronic vulvar disease

          -  Initial vulvar erythema

          -  Vulnerable subjects (particularly adults under guardianship)

          -  Ongoing medical treatment with tricyclic antidepressants or anticonvulsants at
             analgesic doses

        Subject refractory to conventional treatments (tricyclic antidepressants and
        benzodiazepines doses analgesics, physiotherapy type of biofeedback)

        Good understanding and predictable adherence to the protocol beneficiary/affiliated to
        French social security/social healthcare signed Informed Consent Form
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien Pelletier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Besançon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabien Pelletier, MD</last_name>
    <email>fabien.pelletier@univ-fcomte.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabien Pelletier, MD</last_name>
      <email>fabien.pelletier@univ-fcomte.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2016</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>capsaicin</keyword>
  <keyword>pain improvement</keyword>
  <keyword>provoked vulvodynia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvodynia</mesh_term>
    <mesh_term>Vulvar Vestibulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capsaicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

